Pieris Pharmaceuticals (NASDAQ: PIRS) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Volatility & Risk

Pieris Pharmaceuticals has a beta of -73.77, indicating that its share price is 7,477% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.

Profitability

This table compares Pieris Pharmaceuticals and Ardelyx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals -321.83% -221.93% -42.02%
Ardelyx N/A -61.21% -54.11%

Analyst Ratings

This is a breakdown of current ratings for Pieris Pharmaceuticals and Ardelyx, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pieris Pharmaceuticals 0 0 3 0 3.00
Ardelyx 0 0 6 0 3.00

Pieris Pharmaceuticals presently has a consensus price target of $9.00, indicating a potential upside of 48.27%. Ardelyx has a consensus price target of $13.67, indicating a potential upside of 108.65%. Given Ardelyx’s higher probable upside, analysts plainly believe Ardelyx is more favorable than Pieris Pharmaceuticals.

Institutional & Insider Ownership

50.5% of Pieris Pharmaceuticals shares are owned by institutional investors. 4.1% of Pieris Pharmaceuticals shares are owned by company insiders. Comparatively, 15.5% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Pieris Pharmaceuticals and Ardelyx’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pieris Pharmaceuticals $5.83 million 46.63 -$22.79 million ($0.73) -8.32
Ardelyx $24.03 million 12.96 -$112.38 million ($2.23) -2.94

Pieris Pharmaceuticals has higher earnings, but lower revenue than Ardelyx. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Summary

Ardelyx beats Pieris Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

About Ardelyx

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company’s cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.